Skip to main content
SpringerLink
Log in

Disaccharides in the Treatment of Hepatic Encephalopathy

  • Chapter
  • First Online:
Hepatic Encephalopathy

Part of the book series: Clinical Gastroenterology ((CG))

  • 1404 Accesses

Abstract

Hepatic encephalopathy (HE) is a challenging clinical complication of liver dysfunction with a wide spectrum of neuropsychiatric abnormalities that range from mild disturbances in cognitive function and consciousness to coma and death. The uncertainties on the pathogenesis of HE limit the development of specific pharmacological therapies but a key role is thought to be played by circulating gut-derived toxins of the nitrogenous compounds, most notably ammonia. Management of HE primarily involves avoidance of precipitating factors and administration of various ammonia-lowering therapies such as nonabsorbable disaccharides and select antimicrobial agents mostly rifaximin. The nonabsorbable disaccharides include lactulose and lactitol. Nonabsorbable disaccharides are considered the first-line therapy for treatment of acute HE, and improvement in symptoms occurs in 67–87%. Lactitol is comparable to lactulose in the treatment of HE with fewer side effects. Lactulose has also shown to be effective in primary and secondary prophylaxis of HE. Lactulose significantly improves cognitive function and health-related quality of life in patients with minimal hepatic encephalopathy. In a systematic review, the efficacy of nonabsorbable disaccharides was compared with either no intervention or placebo; the overall treatment effect was modest but statistically significant, with a relative risk of no improvement ranging from 0.62 to 0.92.82. There is insufficient evidence to support or refute the use of nonabsorbable disaccharides for HE.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy—definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716–21.

    Article  PubMed  Google Scholar 

  2. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N Engl J Med. 1997;337: 473–9.

    Article  PubMed  CAS  Google Scholar 

  3. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology. 2009;50(6):2014–21.

    Article  PubMed  Google Scholar 

  4. Bajaj JS, Hafeezullah M, Hoffmann RG, Saeian K. Minimal hepatic encephalopathy: a vehicle for accidents and traffic violations. Am J Gastroenterol. 2007;102:1903–9.

    Article  PubMed  Google Scholar 

  5. Groeneweg M, Quero JC, De Bruijn I, Hartmann IJC, Essink-bot MI, Hop WCJ, et al. Subclinical hepatic encephalopathy impairs daily functioning. Hepatology. 1998;28:45–9.

    Article  PubMed  CAS  Google Scholar 

  6. Bajaj JS, Stein AC, Dubinsky RM. What is driving the legal interest in hepatic encephalopathy? Clin Gastroenterol Hepatol. 2011;9(2):97–8.

    Article  PubMed  Google Scholar 

  7. Bajaj JS, Saeian K, Schubert CM, Hafeezullah M, Franco J, et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology. 2009;50(4):1175–83.

    Article  PubMed  Google Scholar 

  8. Bismuth M, Funakoshi N, Cadranel JF, Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol. 2011;23(1):8–22.

    Article  PubMed  Google Scholar 

  9. Albrecht J, Zielińska M, Norenberg MD. Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal. Biochem Pharmacol. 2010;80(9):1303–8.

    Article  PubMed  CAS  Google Scholar 

  10. Lockwood A, Yap E, Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. J Cereb Blood Flow Metab. 1991;11:337–41.

    Article  PubMed  CAS  Google Scholar 

  11. Shawcross DL, Olde Damink SW, Butterworth RF, Jalan R. Ammonia and hepatic encephalopathy: the more things change, the more they remain the same. Metab Brain Dis. 2005;20(3): 169–79.

    Article  PubMed  CAS  Google Scholar 

  12. Haussinger D, Kircheis G, Fischer R, et al. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low grade cerebral edema. J Hepatol. 2000;32: 1035–8.

    Article  PubMed  CAS  Google Scholar 

  13. Tanigami H, Rebel A, Martin LJ, et al. Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats. Neuroscience. 2005;131:437–49.

    Article  PubMed  CAS  Google Scholar 

  14. Cordoba J, Alonso J, Rovira A, Jacas C, Sanpedro F, Castells L, et al. The development of low-grade cerebral oedema in cirrhosis is supported by the evolution of 1H-magnetic resonance abnormalities after liver transplantation. J Hepatol. 2001;35:598–604.

    Article  PubMed  CAS  Google Scholar 

  15. Balata S, Olde Damink S, Ferguson K, Marshall I, Hayes P, Deutz N, et al. Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. Hepatology. 2003;37:931–9.

    Article  PubMed  CAS  Google Scholar 

  16. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968–76.

    Article  PubMed  CAS  Google Scholar 

  17. Riggio O, Balducci G, Ariosto F, et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portosystemic shunt. Dig Dis Sci. 1989;34(6):823–9.

    Article  PubMed  CAS  Google Scholar 

  18. Morgan MY, Hawley KE. Lactitol vs lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial. Hepatology. 1987;7(6):1278–84.

    Article  PubMed  CAS  Google Scholar 

  19. Heredia D, Teres J, Orteu N, et al. Lactitol vs. lactulose in the treatment of chronic recurrent portosystemic encephalopathy. J Hepatol. 1988;7:106–10.

    Article  PubMed  CAS  Google Scholar 

  20. Cordóba J, Blei AT. Treatment of hepatic encephalopathy. Am J Gastroenterol. 1997;92(9): 1429–39.

    PubMed  Google Scholar 

  21. Clausen MR, Mortensen PB. Lactulose, disaccharides and colonic flora: clinical consequences. Drugs. 1997;53(6):930–42.

    Article  PubMed  CAS  Google Scholar 

  22. Eroglu Y, Byrne W. Hepatic encephalopathy. Emerg Med Clin North Am. 2009;27:401–14.

    Article  PubMed  Google Scholar 

  23. Simmons F, Goldstein H, Boyle JD. A controlled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology. 1970;59:827–32.

    PubMed  CAS  Google Scholar 

  24. Rodgers Jr JB, Kiley JE, Balint JA. Comparison of results of long-term treatment of chronic hepatic encephalopathy with lactulose and sorbitol. Am J Gastroenterol. 1973;60:459–65.

    PubMed  Google Scholar 

  25. Corazza GR, Tacconi C, Zoli G, Somarolli M, D’Ambro A, Bernardi M. Use of pyridoxine-alpha-ketoglutarate (PAK) in hepatic encephalopathy. Int J Clin Pharmacol Res. 1982;2:7–13.

    Google Scholar 

  26. Uribe M, Campollo O, Vargas F, Ravelli GP, Mundo F, Zapata L. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portosystemic encephalopathy: a double-blind, randomized clinical trial. Hepatology. 1987;7:639–43.

    Article  PubMed  CAS  Google Scholar 

  27. Horsmans Y, Solbreux PM, Daenens C, et al. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. Aliment Pharmacol Ther. 1997;11(1):165–70.

    Article  PubMed  CAS  Google Scholar 

  28. Watanabe A, Sakai T, Sato S, et al. Clinical efficacy of lactulose in cirrhotic patients with and without subclinical hepatic encephalopathy. Hepatology. 1997;26(6):1410–4.

    Article  PubMed  CAS  Google Scholar 

  29. Dhiman RK, Sawhney MS, Chawla YK, et al. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. Dig Dis Sci. 2000;45(8):1549–52.

    Article  PubMed  CAS  Google Scholar 

  30. Prasad S, Dhiman RK, Duseja A, et al. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45(3):549–59.

    Article  PubMed  Google Scholar 

  31. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ. 2004;328(7447):1046.

    Article  PubMed  CAS  Google Scholar 

  32. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;(2):CD003044.

    Google Scholar 

  33. Lanthier PL, Morgan MY. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut. 1985;26:415–20.

    Article  PubMed  CAS  Google Scholar 

  34. Heredia D, Terés J, Orteu N, Rodés J. Lactitol vs. lactulose in the treatment of chronic recurrent portosystemic encephalopathy. J Hepatol. 1988;7(1):106–10.

    Article  PubMed  CAS  Google Scholar 

  35. Morgan MY, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. J Hepatol. 1989;8(2):208–17.

    Article  PubMed  CAS  Google Scholar 

  36. Riggio O, Balducci G, Ariosto F, Merli M, Pieche U, Pinto G, et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portosystemic shunt. Dig Dis Sci. 1989;34(6):823–9.

    Article  PubMed  CAS  Google Scholar 

  37. Grandi M, Sacchetti C, Pederzoli S, Celani MF. A clinical comparative study of crystalline pure lactulose and powder pure lactitol in portosystemic encephalopathy of cirrhotic patients. Minerva Gastroenterol Dietol. 1991;37(4):225–30.

    PubMed  CAS  Google Scholar 

  38. Pai CH, Huang YS, Jeng WC, Chan CY, Lee SD. Treatment of porto-systemic encephalopathy with lactitol versus lactulose: a randomized controlled study. Zhonghua Yi Xue Za Zhi (Taipei). 1995;55(1):31–6.

    CAS  Google Scholar 

  39. Blanc P, Daures JP, Rouillon JM, Peray P, Pierrugues R, et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology. 1992;15(2): 222–8.

    Article  PubMed  CAS  Google Scholar 

  40. Cammà C, Fiorello F, Tinè F, Marchesini G, Fabbri A, et al. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci. 1993;38(5):916–22.

    Article  PubMed  Google Scholar 

  41. Conn HO, Leevy CM, Vlacevic ZR, Rodgers JB, Maddrey WC, Seef L. Comparison of lactulose and neomycin in the treatment of chronic portosystemic encephalopathy. A double blind controlled trial. Gastroenterology. 1977;72:573–83.

    PubMed  CAS  Google Scholar 

  42. Atterbury CE, Maddrey WC, Conn HO. Neomycin-sorbitol and lactulose in the treatment of acute portosystemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis. 1978;23:398–406.

    Article  PubMed  CAS  Google Scholar 

  43. Orlandi F, Freddara U, Candelaresi MT, Morettini A, Corazza GR, Di Simone A. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci. 1981;26:498–506.

    Article  PubMed  CAS  Google Scholar 

  44. Blanc P, Couderc M, Peray P, Liautard J, Larrey D, Michel H, et al. Lactitol versus vancomycin in the treatment of acute hepatic encephalopathy: a double blind, randomized trial [abstract]. Gut. 1993;34:46.

    Article  Google Scholar 

  45. Mullen K, Prakash R. Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol. 2010;4(6):665–77.

    Article  PubMed  CAS  Google Scholar 

  46. Festi D, Mazzella G, Orsini M, et al. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res. 1993;54(5): 598–609.

    Article  Google Scholar 

  47. Palmer M. The antibiotic rifaximin improves hepatic encephalopathy symptoms in patients with cirrhosis due to hepatitis C virus. Pract Gastroenterol. 2007;31(2):72–6.

    Google Scholar 

  48. Puxeddu A, Quartini M, Massimetti A, Ferrieri A. Rifaximin in the treatment of chronic hepatic encephalopathy. Curr Med Res Opin. 1995;13(5):274–81.

    Article  PubMed  CAS  Google Scholar 

  49. Sama C, Morselli-Labate AM, Pianta P, Lambertini L, Berardi S, Martini G. Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: an open-label, pilot study. Curr Ther Res. 2004;65(5):413–22.

    Article  CAS  Google Scholar 

  50. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin. 1993;13(2):109–18.

    Article  PubMed  CAS  Google Scholar 

  51. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vicchio BD. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol. 2003;49:53–62.

    PubMed  CAS  Google Scholar 

  52. Massa P, Vallerino E, Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res. 1993;4:7–18.

    Google Scholar 

  53. Mas A, Rodes J, Sunyer L, Rodrigo L, Planas R, Vargas V. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol. 2003;38:51–8.

    Article  PubMed  CAS  Google Scholar 

  54. Fera G, Agostinacchio F, Nigro M, et al. Rifaximin in the treatment of hepatic encephalopathy. Eur J Clin Res. 1993;4:57–66.

    Google Scholar 

  55. Leevy CB, Phillips JA. Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci. 2007;52:737–41.

    Article  PubMed  CAS  Google Scholar 

  56. Paik YH, Lee KS, Han KH, et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J. 2005;46(3):399–407.

    Article  PubMed  CAS  Google Scholar 

  57. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol. 2008;20(11):1064–70.

    Article  PubMed  CAS  Google Scholar 

  58. Loguercio C, Del Vecchio Blanco C, Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. J Int Med Res. 1987;15(6):335–43.

    PubMed  CAS  Google Scholar 

  59. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology. 1992;16(1): 138–44.

    Article  PubMed  CAS  Google Scholar 

  60. Fiaccadori F, Ghinelli F, Pelosi G, et al Selective amono acid solutions in hepatic encephalopathy treatment (a preliminary report). Ric Clin Lab. 1980;10(2):411–22.

    Google Scholar 

  61. Rossi-Fanelli F, Riggio O, Cangiano C, Cascino A, De Conciliis D, Merli M, et al. Branched-chain amino acids vs lactulose in the treatment of hepatic coma: a controlled study. Dig Dis Sci. 1982;27(10):929–35.

    Article  PubMed  CAS  Google Scholar 

  62. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev. 2003;(2):CD001939.

    Google Scholar 

  63. Romero-Gomez M, Boza F, Garcia-Valdecasas MS, García E, Aguilar-Reina J. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy. Am J Gastroenterol. 2001;96:2718–23.

    PubMed  CAS  Google Scholar 

  64. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol. 2001;16:531–5.

    Article  PubMed  CAS  Google Scholar 

  65. Hartmann IJ, Groeneweg M, Quero JC, Beijeman SJ, de Man RA, Hop WC, et al. The prognostic significance of subclinical hepatic encephalopathy. Am J Gastroenterol. 2000;95:2029–34.

    Article  PubMed  CAS  Google Scholar 

  66. Sharma P, Agrawal A, Sharma BC, Sarin SK. Primary prophylaxis of hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versus no lactulose. Indian J Gastroenterol. 2010;29 Suppl 1:A8.

    Google Scholar 

  67. Sharma P, Agrawal A, Sharma BC, Sarin SK. Prophylaxis of hepatic encephalopathy in acute variceal bleed: a randomized controlled trial of lactulose versus no lactulose. J Gastroenterol Hepatol. 2011;26(6):996–1003.

    Article  PubMed  Google Scholar 

  68. Riggio O, Masini A, Efrati C, et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. J Hepatol. 2005;42:674–9.

    Article  PubMed  CAS  Google Scholar 

  69. Sharma BC, Sharma P, Agrawal A, et al. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology. 2009;137:885–91.

    Article  PubMed  CAS  Google Scholar 

  70. Bass NM, Mullen KD, Sanyal A, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.

    Article  PubMed  CAS  Google Scholar 

  71. Sanyal A, Bass N, Mullen K, et al. Rifaximin treatment improved quality of life in patients with hepatic encephalopathy: results of a large, randomized, placebo-controlled trial [abstract 15]. J Hepatol. 2010;52 Suppl 1:S7.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, 110070, India

    Praveen Sharma MD, DM & Shiv Kumar Sarin MD, DM, FNA, FNASc

Authors
  1. Praveen Sharma MD, DM
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shiv Kumar Sarin MD, DM, FNA, FNASc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shiv Kumar Sarin MD, DM, FNA, FNASc .

Editor information

Editors and Affiliations

  1. , Division of Gastroenterology, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, 44145, USA

    Kevin D. Mullen

  2. , Division of Gastroenterology, MetroHealth Medical Center, 2500 MetroHealth Medical Center, Cleveland, 44145, USA

    Ravi K. Prakash

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sharma, P., Sarin, S.K. (2012). Disaccharides in the Treatment of Hepatic Encephalopathy. In: Mullen, K., Prakash, R. (eds) Hepatic Encephalopathy. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-836-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-836-8_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-835-1

  • Online ISBN: 978-1-61779-836-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation